national system also controls for differences in case selection, data management and demo graphic descriptions of regional populations. To meet this need, a national laboratory-based antimicrobial resistance surveillance system for nosocomial pathogens was established in 2010, which included Klebsiella pneumoniae as a sentinel organ ism by which to monitor resistance.
K. pneumoniae is an important nosocomial pathogen, with the highest prevalence of resistance to third-and fourthgene ration cephalosporins among the Enterobacteriaceae. The spread of class A or group 2be extended-spectrum betalactamases (ESBLs) in Enterobacteriaceae is of public health concern. The most frequently detected and clinically important ESBLs belong to the TEM, SHV, and CTX-M families, and K. pneumoniae commonly produces all three groups of enzymes. [2] In the past decade, CTX-M enzymes have emerged as the most prevalent type. There are more than 100 different types, which can be broadly divided into five groups based on their amino-acid identities: CTX-M1, CTX-M2, CTX-M8, CTX-M9 and CTX-M25. Enzymes are characterised by epidemiological differences, and some have even been shown to spread beyond the hospital environment into the community. [2] Of further public health concern are the recent emergence of K. pneumoniae strains capable of producing carbapenem-hydrolysing enzymes and the apparent ease of spread of resistance mechanisms by mobile genetic elements. [2] There are few published reports on national antimicrobial resistance rates of K. pneumoniae in South Africa (SA), with data primarily emanating from the private sector, [3] regional studies with limited numbers of local isolates [1] or certain clinical settings. [4] To date, molecular data on ESBL K. pneumoniae in SA are based on detailed studies of small populations. Essack et al. [5] examined bla SHV and bla TEM genes in 25 isolates, and found a high degree of diversity in terms of plasmids present, genes detected and the combination of genes within isolates. In a study of ESBL K. pneumoniae from seven countries in 2003, bla TEM-10 , bla , bla TEM-63 , various bla SHV-2 and bla SHV-5 types, bla CTX-M2 and bla CTX-M3 genes were detected in 27 SA isolates. [6] A more recent study on 53 ESBL clinical pathogens from Pretoria detected bla TEM , bla SHV and bla CTX-M-1 genes, although the contribution of the 31 K. pneumoniae isolates in this group was not specified. [7] This diversity in enzyme production and the prolific nature of K. pneumoniae as a nosocomial pathogen highlight the need for further investigation into the genes responsible for these enzymes in the SA setting.
In this study, we determined the antibiotic susceptibility profiles of K. pneumoniae isolates from bacteraemic patients with positive blood cultures from sentinel sites representing five SA regions. We used national laboratory-based surveillance data to characterise the third-and fourthgeneration cephalosporin-resistant and carba penem-resistant phenotypes and genotypes of K. pneumoniae from 2010 to 2012.
Methods

Patient selection
Thirteen academic centres serving the public healthcare sector in SA were included, and participation was voluntary. The sites represented regions in Gauteng, KwaZuluNatal, Free State, Limpopo and Western Cape provinces. Isolates of K. pneumoniae from patients with bloodstream infections were submitted, with a 3-week exclusion thereafter to avoid duplicate isolates of the same organism.
Phenotypic methods
K. pneumoniae isolates were submitted on Dorset transport media. Organism identification was confirmed using the Vitek 2 GN card (Biomerieux, France). Susceptibility testing and determination of ESBL phenotype was performed on the MicroScan Walkaway (Siemens Healthcare Diagnostics, USA), using NM37 panels. Categorical results and susceptibility profile of each antimicrobial agent tested were based on 2012 Clinical Laboratory Standards Institute (CLSI) interpretative criteria, [8] the European Committee on Antimicrobial Susceptibility Testing guidelines [9] and/ or the MicroScan recommendations. The MIC 50 and MIC 90 (minimum inhibitory concentrations needed to inhibit the growth of 50% and 90% of organisms, respectively) were determined. The Agresti-Coull interval method was used to calculate confidence intervals, and a χ 2 test was performed to analyse trends in antibiotic susceptibility. A p-value of <0.05 was deemed statistically significant.
Genotypic methods
Two hundred and seventy ESBLproducing isolates were randomly selected (approximately 14% per region) and screened for the presence of ESBL genes. DNA was extracted from half a loop (~2 mm in diameter) of bacterial culture. This was resuspended in 400 µl trisethylenediaminetetraacetic acid buffer (pH 8.0), vortexed briefly, heated at 95°C for 25 minutes and pelleted by centrifugation. The supernatant was aliquoted and stored at -70°C for further use.
The LightCycler 480 instrument (Roche Applied Science, Germany) and LightCycler 480 Probes Master kit (Roche Diagnostics, USA) were used for real-time polymerase chain reaction (PCR). The bla TEM and bla SHV genes were amplified by multiplex real-time PCR using the primers shown in Table 1 . The primers were selected for specificity by GenBank comparisons and PCR products from control strains were sequenced. The limit of detection was determined to be 750 colony-forming units (cfu)/ml for bla TEM and 4 000 cfu/ml for bla SHV . The reaction conditions were 0.5 μM primers, 0.2 μM probes, denaturation for 95°C for 5 minutes, and then 45 cycles of 95°C for 10 seconds, 55°C for 30 seconds and 72°C for 1 second. The bla CTX-M PCR was a multiplex assay targeting bla CTX-M groups M1 and M2-9 using primer and probe sequences as described previously. [10] Detection of bla NDM-1 and bla KPC genes was performed on isolates with reduced susceptibility to carbapenems as described previously.
[11] Reduced susceptibility to carbapenems was defined according to the CLSI guidelines of 2012. [8] Strains from the 
Results
A total of 2 774 discrete K. pneumoniae isolates were received and included in the antimicrobial susceptibility testing over the 3-year period. The majority of isolates demonstrated an ESBL phenotype (68.3%) with marked resistance to third-and fourthgeneration cephalosporins. The distribution of isolates according to province, and ESBL rates, are shown in Table 2 . A breakdown of susceptibility by agent for the 3-year period is presented in Fig. 1 . Reduced carbapenem susceptibility was noted in only 124 (4.5%) of isolates ( Table 2) . The carbapenemase genes bla NDM-1 and bla KPC were not detected in any of the 124 isolates and the presence of other carbapenemaseproducing genes was not investigated.
Susceptibility to aminoglycosides over the 3-year period was variable, with 95.3% susceptible to amikacin but only 31.1% and 31.3% susceptible to tobramycin and gentamicin, respectively (Fig. 1) . Susceptibility to levofloxacin (75.2%) was higher than to ciprofloxacin (53.5%). Sixty-seven (66.9%) per cent of all isolates were susceptible to piperacillin-tazobactam (MIC 50 = 8 µg/ml) for the 3 years, and sus ceptibility to cefoxitin was high at 87.4% (Table 3) .
Trend analysis was performed on the isolates, comparing the susceptibility rates between 2010, 2011 and 2012 (Table 4) . Small but statistically significant declines in susceptibility rates were noted for many antibiotics, including amoxicillin/ clavulanate, tobramycin, gentamicin, ciprofloxacin, ceftazidime and cefotaxime.
Molecular characterisation was performed on 270 ESBL-positive isolates. All phenotypically ESBL-positive isolates were confirmed to possess one or more of the bla CTX-M , bla SHV and bla TEM genes, with 93.0% of the isolates tested expressing more than one resistance gene (Fig. 2) .
Discussion
Gauteng contributed the majority of isolates in the study (62.6%), probably because it is the most populous province with the largest academic centres. The high percentage of bacteraemic K. pneumoniae that were resistant to third-generation cephalosporins (68.3%) is of serious public health concern. Rates of resistance in a 2006 study from SA private laboratories showed 52% resistance to cefuroxime, 46% to ceftriaxone and 44% to cefepime. [3] A study of resistance at seven public sector hospitals between 2010 and 2012 reported an overall level of ESBL detection of 65%.
[12] Our study shows a similar rate (68.3%) of resistance to extended-spectrum cephalosporins. The difference between the private and public sectors may indicate a dramatic increase in development of resistance in the interim, and/or a difference in sampling and resistance patterns between these sectors. Also, because they are referral centres, the academic centres that submitted isolates in this study potentially contributed a disproportionate number of patients who were more likely to harbour ESBL isolates. Globally, reports show a trend towards an increase in resistance of K. pneumoniae to third-generation cephalosporins. [13] While rates of resistance are low in some countries, [9] ) August 2014, Vol. 104, No. 8 e.g. 11.5% in 2010 in the USA, [13] higher rates have been observed in other regions. [14] This laboratory-based surveillance also under lines the endemic distribution of all three major groups of ESBL genes throughout five regions of SA. The almost identical susceptibility pattern to cefotaxime, ceftazidime and cefepime suggests that there are multiple copies of several ESBL genes in the sample, which is supported by the genotypic results. A limitation of the study is that the genotypic data represent only 14% of K. pneumoniae isolates from selected academic or referral laboratories, and may not be fully representative at a national level. The phenotypic data support the genotypic data, however, being fairly representative of all isolates sampled in this survey. These results are also a first indication of the extensive prevalence of bla SHV , bla TEM and bla CTX-M genes in geographically distinct regions of SA.
Susceptibility to carbapenems was high, with only 4.5% of isolates showing reduced susceptibility. However, carbapenem-resistant Enterobacteriaceae have been described in SA, [15] and levels of carbapenem resistance need to be monitored closely. It must also be noted that the breakpoints for ertapenem have since been revised by the CLSI. [8] A limitation of this study is that we only tested for bla NDM-1 and bla KPC genes and did not investigate for other potential mechanisms of carbapenem resistance.
For piperacillin-tazobactam, the MIC 50 was within the susceptible breakpoint while the MIC 90 was above the resistant breakpoint. Overall susceptibility was 66.9%, and piperacillin-tazobactam may therefore be a potentially useful agent for treatment. However, there is still debate concerning the use of piperacillintazobactam to treat infections with ESBLproducing Enterobacteriaceae. There is some evidence that outcomes may be worse if the piperacillin-tazobactam MIC is 8 -16 mg/l, with suggestions that if piperacillintazobactam is used to treat organisms with these MICs, prolonged infusions or more frequent dosing may be needed. [16] The 87.4% susceptibility to cefoxitin suggests that plasmid-mediated AmpC enzymes are not particularly prevalent in this sample. The disparity in ciprofloxacin and levofloxacin resistance (21.7% difference) is intriguing and although we do not have genotypic data to support it, it may represent an increase in quinolone resistance mechanisms (e.g. plasmid-mediated mechanisms; enzymatic modification) other than the conventional target site mutations, where one would expect cross-resistance [17] as 61.5% ESBL of K. pneumoniae iso lates were resistant to ciprofloxacin.
Among all aminoglycosides, amikacin exhibited the best activity, although this must be interpreted with caution as the stipulated breakpoints are high considering that this is a concentration-dependent agent. The MIC 50 and MIC 90 of 8 µg/ml and 16 µg/ml, respectively, indicate that for many isolates the probability of achieving adequate serum levels is quite low.
Overall, the MIC 50 and MIC 90 to most agents have not changed over the 3-year period, although the ability to detect smaller differences may have been limited by the methodological system employed for susceptibility testing. The one exception was colistin, for which a significant increase in MIC 90 was noted in 2012 (p=0.001) ( Table  4) . This is alarming, as colistin represents the mainstay of the treatment of most of our extensively drug-resistant Gram-negative pathogens (including carbapenem-resistant K. pneumoniae). [18] Trends in susceptibility showed a significant decrease over the study period for most antimicrobial agents, with a few exceptions, e.g. piperacillin-tazobactam, levofloxacin and tigecycline.
A limitation of this study was that comprehensive patient demographic details were unavailable, and it was not possible to determine accurate trends in patient age, ward and gender. This information will be obtained in future surveys, allowing for more detailed analyses of antimicrobial resistance patterns, and how they change over time.
These surveillance results should be used together with hospital-specific data as tools in antimicrobial stewardship programmes and for the development of empiric therapy guidelines for healthcare-associated infections. Ongoing antimicrobial resistance surv eillance, performed in a systematic and standardised manner, could be used as a tool to monitor the effectiveness of antimicrobial stewardship programmes that have been implemented in various centres across the country. Moreover, it provides a foundation for the systematic surveillance of important hospital pathogens that could be expanded and enhanced over time.
Conclusion
SA appears to have a relatively high percentage of ESBL-producing K. pneumoniae isolates in comparison with other geographical regions, which is of great concern, and a significant increase in ertapenem resistance over the surveillance period. This study presents the antibiotic resistance patterns of invasive K. pneumoniae isolates and gives an indication of the prevalence of resistance genes. Our findings provide important baseline data for further site-specific analysis of K. pneumoniae isolates, as well as a platform for enhanced surveillance of K. pneumoniae antimicrobial resistance in the country. Additionally, when analysed in conjunction with patient demographic and clinical details these data are important for the development of empiric therapy guidelines for management of sepsis in SA healthcare institutions. 
